ATE161423T1 - Verwendung von phosphinate zur behandlung der osteoporose - Google Patents

Verwendung von phosphinate zur behandlung der osteoporose

Info

Publication number
ATE161423T1
ATE161423T1 AT93914339T AT93914339T ATE161423T1 AT E161423 T1 ATE161423 T1 AT E161423T1 AT 93914339 T AT93914339 T AT 93914339T AT 93914339 T AT93914339 T AT 93914339T AT E161423 T1 ATE161423 T1 AT E161423T1
Authority
AT
Austria
Prior art keywords
high potency
day
thirty
potency phosphonate
phosphonate compound
Prior art date
Application number
AT93914339T
Other languages
English (en)
Inventor
Marion David Francis
Rogely Waite Boyce
Original Assignee
Procter & Gamble Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25422708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE161423(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble Pharma filed Critical Procter & Gamble Pharma
Application granted granted Critical
Publication of ATE161423T1 publication Critical patent/ATE161423T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93914339T 1992-06-30 1993-06-04 Verwendung von phosphinate zur behandlung der osteoporose ATE161423T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90660992A 1992-06-30 1992-06-30

Publications (1)

Publication Number Publication Date
ATE161423T1 true ATE161423T1 (de) 1998-01-15

Family

ID=25422708

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93914339T ATE161423T1 (de) 1992-06-30 1993-06-04 Verwendung von phosphinate zur behandlung der osteoporose

Country Status (13)

Country Link
EP (1) EP0648120B1 (de)
JP (2) JP4481368B2 (de)
KR (1) KR950702120A (de)
AT (1) ATE161423T1 (de)
AU (1) AU659329B2 (de)
CA (1) CA2138367C (de)
DE (1) DE69316013T2 (de)
DK (1) DK0648120T3 (de)
ES (1) ES2111163T3 (de)
GR (1) GR3025792T3 (de)
HU (1) HUT70210A (de)
MA (1) MA22915A1 (de)
WO (1) WO1994000129A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727629A1 (fr) * 1994-12-06 1996-06-07 Sanofi Sa Trousse pour cycle de traitement de l'osteoporose
JP3796693B2 (ja) * 1994-12-28 2006-07-12 ガドール エス アー オルパドロネートからなる骨塊同化組成物
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
TR200000145T2 (tr) * 1997-07-22 2000-05-22 Merck & Co. Inc. Kemik erimesini durdurmak için bir yöntem
AU2007211965B2 (en) * 1997-07-22 2008-05-15 Merck Sharp & Dohme Corp. Alendronate for use in the treatment of osteoporosis
AU2005227418B2 (en) * 1997-07-22 2008-05-29 Merck Sharp & Dohme Corp. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
CA2410201C (en) 2000-06-20 2010-10-26 Novartis Ag Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
RU2387451C2 (ru) 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
ITPA20070034A1 (it) * 2007-10-30 2009-04-30 Tetrapharm S R L Bifosfonati geminali, loro preparazione e loro impiego in campo oncologico.
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
TWI730039B (zh) 2016-01-29 2021-06-11 日商富士藥品股份有限公司 新穎雙膦酸化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH27078A (en) * 1984-12-21 1993-02-01 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonates
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
DE4011777A1 (de) * 1989-04-14 1990-10-18 Ciba Geigy Ag N-trisubstituierte aminoalkandiphosphonsaeuren

Also Published As

Publication number Publication date
CA2138367A1 (en) 1994-01-06
WO1994000129A1 (en) 1994-01-06
EP0648120B1 (de) 1997-12-29
GR3025792T3 (en) 1998-03-31
HUT70210A (en) 1995-09-28
JP2010106042A (ja) 2010-05-13
AU4403893A (en) 1994-01-24
EP0648120A1 (de) 1995-04-19
DK0648120T3 (da) 1998-01-19
MA22915A1 (fr) 1993-12-31
CA2138367C (en) 1998-09-22
ES2111163T3 (es) 1998-03-01
JPH07508278A (ja) 1995-09-14
DE69316013T2 (de) 1998-07-09
JP4481368B2 (ja) 2010-06-16
DE69316013D1 (de) 1998-02-05
AU659329B2 (en) 1995-05-11
KR950702120A (ko) 1995-06-19

Similar Documents

Publication Publication Date Title
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
NO933044D0 (no) Fremgangsmaate for behandling av osteoporose
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
KR950702121A (ko) 포스포네이트 및 비스테로이드계 소염 약물(nasid)을 함유하는 관절염 치료 조성물(compositions for the treatment of arthritis containing phosphonates and nsaids)
NO942241L (de)
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
CA2102429A1 (en) Bone growth factors and inhibitors of bone resorption for promoting bone formation
DE3650403T3 (de) Polyphosphonat enthaltende Packung zur Behandlung von Osteoporose.
DE69616333D1 (de) Thip zur behandlung von schlafstörungen
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
GR3022321T3 (en) Use of il-4 to treat solid tumors
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
DE69221725D1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
DE69023006D1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE3875637D1 (de) Zusammensetzungen und verfahren zur behandlung von magengeschwueren.
NO945058L (no) Anvendelse av fosfonater for behandling av osteoporose
ATE150645T1 (de) Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen
ATE74767T1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
ATE86481T1 (de) Dosisform zur verabreichung von calciumantagonisten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked